Abstract Details

Title Longitudinal Progression of Cortical Thinning Differs Across MS Phenotypes and is Clinically Relevant: A Multicentre Study

Topic Multiple Sclerosis

Presentation(s) P2 - Poster Session 2 (8:00 AM-9:00 AM)

Poster/Presentation
Number 9-014

Objective To investigate the distribution and regional evolution of cortical thickness (CTh) reduction in patients with different multiple sclerosis (MS) clinical phenotypes in a multicentre dataset.

Background Grey matter (GM) atrophy is a crucial component of MS and provides clinically relevant pieces of information. The rates of progression of GM atrophy over time in the main MS clinical phenotypes have been rarely studied.

Design/Methods Prospectively, T2- and 3D T1-weigthed images were acquired at 3T from 86 MS patients (75 relapsing-remitting MS [RRMS], 11 progressive MS [PMS]) and 34 healthy controls (HC) at 3 European sites. Neurological assessment and MRI were performed at baseline and after one-year. Patients were classified as clinically stable or worsened according to their EDSS change. Baseline CTh differences and changes over time were assessed on 3D T1-weighted images using Freesurfer in the whole MS group, in the main MS clinical phenotypes as well as in patients with and without disability progression.

Results At baseline, temporal and occipital atrophy was found in MS patients vs HC. RRMS patients mainly showed CTh loss in bilateral superior temporal and occipital regions vs HC, while PMS patients showed additional CTh reduction vs RRMS, mostly in inferior frontal regions. During the follow-up, MS patients showed significant within-group cortical thinning mainly in frontal, parietal and temporal areas, whereas no CTh changes were observed in HC. RRMS patients showed significant within-group cortical thinning over time mainly in superior frontal, parietal and occipital cortices (p<0.01 vs HC). In PMS patients, cortical thinning mainly involved the inferior frontal and temporal pole cortices, with a significant time-by-group interaction vs RRMS in these latter regions. Finally, cortical thinning was higher in frontal and temporal regions in clinically worsened (n=8) vs stable MS patients.

Conclusions One-year cortical thinning progression was variable across MS phenotypes and contributed to explain clinical worsening.

Authors/Disclosures
Milagros Hidalgo de la Cruz PRESENTER	Milagros Hidalgo de la Cruz has nothing to disclose.
Maria A. Rocca (Neuroimaging Research Unit)	Maria Assunta Rocca has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen, Bristol Myers Squibb, Eli Lilly, Janssen, Roche. Maria Assunta Rocca has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for AstraZaneca, Biogen, Bristol Myers Squibb, Bromatech, Celgene, Genzyme, Horizon Therapeutics Italy, Merck Serono SpA, Novartis, Roche, Sanofi and Teva. The institution of Maria Assunta Rocca has received research support from MS Society of Canada, the Italian Ministry of Health, the Italian Ministry of University and Research, and Fondazione Italiana Sclerosi Multipla.
Paola Valsasina	Paola Valsasina has nothing to disclose.
Claudio Gobbi, MD (Ospedale Regionale Lugano)	Dr. Gobbi has nothing to disclose.
Antonio Gallo	Antonio Gallo has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sanofi. Antonio Gallo has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Antonio Gallo has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck. Antonio Gallo has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis.
Chiara Zecca, MD (Ente ospedaliero cantonale)	Prof. Zecca has nothing to disclose.
Alvino Bisecco	Alvino Bisecco has nothing to disclose.
Massimo Filippi, MD, F�鶹��ýӳ�� (Ospedale San Raffaele, Neuroimaging Research Unit)	Dr. Filippi has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Alexion, Almirall, Biogen, Merck, Novartis, Roche, Sanofi. Dr. Filippi has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion, Biogen, Bristol-Myers Squibb, Merck, Novartis, Roche, Sanofi, Sanofi-Aventis, Sanofi-Genzyme, Takeda. Dr. Filippi has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Bayer, Biogen, Celgene, Chiesi Italia SpA, Eli Lilly, Genzyme, Janssen, Merck-Serono, Neopharmed Gentili, Novartis, Novo Nordisk, Roche, Sanofi, Takeda, and TEVA. Dr. Filippi has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Springer Nature. The institution of Dr. Filippi has received research support from Biogen Idec, Merck-Serono, Novartis, Roche, the Italian Ministry of Health, the Italian Ministry of University and Research, and Fondazione Italiana Sclerosi Multipla.

�鶹��ýӳ��

�鶹��ýӳ��